The Global HumanRecombinant Insulin Market, by Product Type (Rapid-Acting Human Insulin,Short-Acting Human Insulin, Intermediate-Acting Human Insulin, Long-ActingHuman Insulin, and Premixed Human Insulin), by Brand (Humalog, Novolog, Apidra,Humulin R, Novolin R, Humulin N, Novolin N, Levemir, Lantus, Humalog Mix,Novolog Mix, and Others), By Distribution Channel (Hospital Pharmacies, RetailPharmacies, and Online Pharmacies) was valued US$ 27.4 billion in 2018, and isprojected to exhibit a CAGR of 7.2% over the forecast period (2018 - 2026).
Key manufacturers are engaged inlaunching novel human insulin portfolio and gaining regulatory approval for theirinsulin product portfolio. For instance, in August 2014, Eli Lilly and Companylaunched Jardiance (empagliflozin) as a treatment option for Type 2 diabetespatients in the U.S. Jardiance is a sodium glucose co-transporter-2 (SGLT2)inhibitor with Type 2 diabetes patients. In March 2016, Biocon Limitedcollaborated with LaboratoriosPiSA S.A de CV (PiSA) to jointly develop and sella generic recombinant human insulin in America. Biocon expects the product tolaunch by 2020 in the U.S. In February 2018, Novo Nordisk launched Fiaspa: afast-acting mealtime insulin in the U.S. Fiaspa received U.S. FDA approval andindicated to improve glycemic control in adults with type 1 and type 2diabetes. In December 2017, the U.S. Food and Drug Administration (FDA) approvedSanofi’s Admelog. Admelog is a follow-on mealtime insulin, which helps peopleliving with diabetes manage blood sugar levels at mealtime.
* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/1797
Browse 35 Market Data Tables and42 Figures spread through 205 Pages and in-depth TOC on "Human RecombinantInsulin Market, by Product Type (Rapid-Acting Human Insulin, Short-Acting HumanInsulin, Intermediate-Acting Human Insulin, Long-Acting Human Insulin, andPremixed Human Insulin), by Brand (Humalog, Novolog, Apidra, Humulin R, NovolinR, Humulin N, Novolin N, Levemir, Lantus, Humalog Mix, Novolog Mix, andOthers), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, andOnline Pharmacies) - Global Forecast to 2026"
Efficient diabetes management andease of use creates need for advancements in current solutions of both insulinand its delivery systems thereby, offering reduced patient discomfort. GlucoseResponsive Insulin (GRI) or smart insulin is a novel technology for people withdiabetes, which works by automatically reacting to blood sugar fluctuations inbody and responds to changing blood glucose levels. The lower or higher bloodsugar levels are lead to release of more or less insulin, respectively. Smartinsulin decreases the number of regular blood tests required and also minimizesthe number of daily dose of insulin injections. Researchers from the Universityof North Carolina have been working on a smart insulin patch. For instance, in2015, researchers reported that, smart insulin patch can use a micro-needlessystem to automatically detect high blood glucose levels and administer insulinappropriately. Key players in the human recombinant insulin market areimplementing inorganic growth strategies to develop and introduce smart insulintechnology in the market. For instance, in February 2016, Eli Lilly and Companyacquired Glycostasis, Inc., a startup company engaged in developing smartinsulin. Eli Lilly and Company is focused on developing Glycostasis’s ‘smartinsulin’ technology.
Browse ResearchReport: https://www.coherentmarketinsights.com/market-insight/human-recombinant-insulin-market-1797
Key takeaways of the HumanRecombinant Insulin Market:
The global human recombinantinsulin market is expected to expand at a CAGR of 7.2% during the forecastperiod (2018 – 2026), owing to increasing technological advancement inrecombinant human insulin by various key players.
Long acting human insulin are projectedto grow with higher pace during the forecasted period in the product typesegment, owing to their higher efficiency and ability to offer consistentinsulin delivery throughout the day, lasting 24 hours.
Other brands hold major marketshare in brand segment, due to the involvement of innovative and new humanrecombinant insulin portfolio with increased patent expiry period such asToujeo, Tresiba, Basaglar, among others; in this segment, which furtherexpected to capture higher market share, during the forecast period.
Retail pharmacies holds largestmarket share in distribution channel segment. As retail pharmacies offer directaccess to full range of diabetes products, covering all prescription andover-the-counter products for patients with diabetes.
Some of the major playersoperating in global human recombinant insulin market include Novo Nordisk A/S,Eli Lilly and Company, Sanofi S.A., Julphar Gulf Pharmaceutical Industries,Biocon Limited, Bioton S.A., Gan & Lee Pharmaceuticals, Ltd., Zhuhai UnitedLaboratories Co., Ltd., Wanbang Biopharmaceuticals Co., Ltd. and DongbaoEnterprise Group Co., Ltd.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/1797
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN: +050-5539-1737
